1. Home
  2. Companies
  3. OSL
  4. Material Events

Oncosil Medical (ASX:OSL) — Material Events

ASX:OSL · 22 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 1 article Significant 18 articles Notable 3 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
18
OncoSil Medical Hits Record Dose Sales, Expands European Reach, Boosts ManufacturingMedium
OncoSil Medical posts record Q2 dose sales, expands European treatments, and advances manufacturing
30 Jan 2026 ·Quarterly Activities & Cash Flow Report ·85
OncoSil Medical Raises $8M to Accelerate Pancreatic Cancer Device RolloutHigh
OncoSil Medical launches $8M equity raise to accelerate commercialisation of pancreatic cancer radiotherapy device
3 Feb 2026 ·Capital Raising ·85
OncoSil Medical Surges with Record Sales and $8.7M Capital BoostMedium
OncoSil Medical posts record sales growth, secures $8.7M capital raise, advances clinical trials
29 July 2025 ·Quarterly Activities & Cash Flow Report ·85
OncoSil Medical Surges with Record Q1 Cash Receipts and Expands European FootprintMedium
OncoSil Medical reports record Q1 cash receipts, positive clinical results, and European market expansion
30 Oct 2025 ·Quarterly Activities & Cash Flow Report ·85
OncoSil Medical Reports Encouraging OSPREY Registry Interim Results for Pancreatic CancerMedium
OncoSil Medical reports positive interim OSPREY Registry results showing safety and efficacy in pancreatic cancer treatment
15 May 2026 ·Clinical Trial Update ·85
OncoSil’s OSPREY Registry Signals New Hope for Advanced Pancreatic Cancer SurvivalMedium
OncoSil OSPREY Registry Shows Promising Survival Benefit in Advanced Pancreatic Cancer
3 Dec 2025 ·Clinical Data Update ·85
OncoSil Medical Doubles Dose Sales Amid Promising Pancreatic Cancer Trial DataHigh
OncoSil Medical Reports Record Sales, Positive Clinical Data, and $8M Capital Raise in 1H FY26
24 Feb 2026 ·Appendix 4D Half Yearly Report ·85
OncoSil Medical Secures Groundbreaking TGA Approval for Pancreatic Cancer DeviceHigh
OncoSil Medical Secures TGA Approval for Pancreatic Cancer Device in Australia
20 May 2026 ·Regulatory Approval ·85
OncoSil Medical Advances with $15.1M Loss, Key Approvals, and $14M Capital BoostMedium
OncoSil Medical reports $15.1M loss, regulatory approvals, clinical trial completions, and $14M capital raise
29 Aug 2025 ·Preliminary Final Report (Appendix 4E) and Annual Report ·85
OncoSil Raises $8M to Power German Trial and European GrowthMedium
OncoSil Medical Raises $8M to Fund German Trial and European Expansion
3 Feb 2026 ·Capital Raising ·85
OncoSil Medical Dose Sales Surge 60 Percent as Key Trials ProgressHigh
OncoSil Medical Q3 FY26 dose sales surge 60%, key trials advance, new manufacturing facility on track
28 Apr 2026 ·Quarterly Activities & Cash Flow Report ·85
OncoSil Medical Advances FDA Approval Bid for Rare Bile Duct Cancer DeviceHigh
OncoSil Medical files FDA HDE application for OncoSil™ device to treat distal cholangiocarcinoma
3 July 2026 ·Regulatory Filing ·85
OncoSil Medical Validates Manufacturing and Sets Up Australian Production HubMedium
OncoSil Medical Completes Manufacturing Validation and Establishes Scalable Australian Production
13 July 2026 ·Operational Update ·80
OncoSil Medical Launches $2M Entitlement Offer Backed by $6M PlacementMedium
OncoSil Medical launches $2M fully underwritten entitlement offer with $6M placement to fund growth
3 Feb 2026 ·Prospectus ·80
OncoSil’s PANCOSIL Trial Unveils Safer, Smarter Pancreatic Cancer TreatmentMedium
OncoSil's PANCOSIL Study Shows Safe, Feasible CT-Guided Delivery with Promising Survival in Pancreatic Cancer
18 Sept 2025 ·Clinical Trial Results ·80
OncoSil Confirms Timely Disclosure of PANCOSIL Trial Data After CIRSE RevealMedium
OncoSil confirms materiality and compliance in disclosure of PANCOSIL trial results after CIRSE 2025 presentation
29 Sept 2025 ·ASX Query Response ·75
OncoSil Medical Gains Ethics Nod to Double Italian Hospital Network for Pancreatic Cancer DeviceMedium
OncoSil Medical Secures Key Ethics Approval in Italy to Expand OncoSil™ Device Access and Commercial Rollout
28 May 2026 ·Regulatory Approval Announcement ·75
OncoSil Medical Joins European Consortium with Cost-Saving PULSE Trial in Pancreatic CancerMedium
OncoSil Medical joins major European pancreatic cancer consortium with cost-efficient PULSE trial
2 July 2026 ·Clinical Trial Participation Announcement ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.